`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`_________________________
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`_________________________
`
`SAMSUNG BIOEPIS CO., LTD.,
`Petitioner,
`
`v.
`
`REGENERON PHARMACEUTICALS, INC.,
`Patent Owner.
`_________________________
`
`Case IPR2023-00884
`
`U.S. Patent No. 11,253,572
`_________________________
`
`
`PETITIONER’S MOTION TO SEAL
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. §§ 42.14 and 42.54 and the Patent Trial and Appeal
`
`Board Consolidated Trial Practice Guide November 2019, Petitioner Samsung
`
`Bioepis Co., Ltd. (“Petitioner” or “Samsung ”) respectfully submits this Motion to
`
`Seal concurrently with Petitioner’s Reply to Patent Owner Preliminary Response
`
`(“Reply”). Specifically, based on Patent Owner’s representations that a number of
`
`its exhibits are confidential (See, Paper 7, Patent Owner’s Motion to File
`
`Confidential Documents Under Seal), Samsung seeks to seal portions of its Reply
`
`disclosing and analyzing the substance of those exhibits submitted by Patent Owner.
`
`I.
`
`
`
`GOOD CAUSE EXISTS TO SEAL
`
`The standard governing the Board’s determination of whether to grant a
`
`motion to seal is “good cause.” Garmin Int’l, Inc. v. Cuozzo Speed Techs. LLC,
`
`IPR2012-00001, Paper 36 at 4 (April 5, 2013) (quoting 37 C.F.R. § 42.54). The
`
`Board aims to “strike a balance between the public’s interest in maintaining a
`
`complete and understandable file history and the parties’ interest in protecting truly
`
`sensitive information.” Id.
`
`
`
`The portions of the Reply Petitioner seeks to file under seal discuss Patent
`
`Owner’s exhibits that, according to Patent Owner, allegedly contain confidential
`
`business information that would cause competitive harm to Patent Owner were it to
`
`be disclosed publicly. Paper 7, 2-7. Based on Patent Owner’s representations, “good
`
`cause” exists to maintain the portions of the Reply discussing Patent Owner’s
`
`
`
`1
`
`
`
`
`
`allegedly confidential exhibits under seal and available only to the parties and Board.
`
`Pursuant to Paragraph 5(A)(ii) of the Board’s default protective order (Ex. 2059), a
`
`redacted copy of Petitioner’s Reply is being filed publicly.
`
`A. Petitioner’s Reply Discusses Exhibits Patent Owner Has Designated
`Confidential
`Certain portions of Petitioner’s Reply discuss the substance of Exhibits 2015,
`
`
`
`2018, 2019, 2039, 2040, and 2043, previously submitted by the Patent Owner under
`
`seal in this proceeding. See, Reply, 4-10; Paper 7. According to Patent Owner,
`
`Exhibits 2015, 2019, and 2043 are Patent Owner’s internal summaries of its DA
`
`VINCI and VIEW clinical trial results; Exhibit 2018 is a detailed report of Patent
`
`Owner’s DA VINCI clinical trial results; and Exhibits 2039-2040 are Patent
`
`Owner’s internal memoranda, notes, and other planning documents from 2008
`
`related to Patent Owner’s development of aflibercept, and in particular to the design
`
`of aflibercept clinical trials. Id., 2-7.
`
`
`
`In its motion to seal, Patent Owner argues that these documents include non-
`
`public confidential internal memoranda, notes, and other planning documents
`
`concerning Patent Owner’s design of aflibercept clinical trials as well as Patent
`
`Owner’s strategic decision making in the development of Eylea®, including its
`
`
`
`2
`
`
`
`
`
`commercial and regulatory strategies. Id.1 According to Patent Owner, public
`
`release of the details in these exhibits could cause competitive harm to Patent Owner
`
`by giving its competitors knowledge of its clinical research operations. Id. For
`
`purposes of the instant Motion to Seal only, Petitioner does not object to the
`
`confidentiality of Patent Owner’s exhibits referenced in the Reply. On that basis,
`
`the Board should grant this Motion to Seal.
`
`II. CERTIFICATION
`
`
`
`Pursuant to 37 CFR § 42.54, Petitioner certifies that it has conferred with
`
`Patent Owner regarding this motion to seal. Patent Owner does not object to the
`
`motion.
`
`
`
`
`1 Patent Owner further notes that in the district court litigation between Patent
`
`Owner and Mylan, Patent Owner produced these documents with a designation of
`
`“CONFIDENTIAL” as defined by the protective order in that case.
`
`
`
`3
`
`
`
`
`
`DATED: September 18, 2023
`
`
`
`
`
`
`
`
`Respectfully submitted,
`By /Raymond N. Nimrod/
`Raymond N. Nimrod (Reg. No. 31,987)
`raynimrod@quinnemanuel.com
`QUINN EMANUEL URQUHART
`& SULLIVAN LLP
`51 Madison Avenue, 22nd Floor
`New York, NY 10010
`Tel:
`(212) 849-7000
`Fax: (212) 849-7100
`
`
`Attorneys for Petitioner Samsung Bioepis
`
`4
`
`
`
`
`
`CERTIFICATE OF SERVICE
`In accordance with 37 C.F.R. § 42.6(e), I hereby certify that on September 18,
`
`2023, true and correct copies of Petitioner’s Motion to Seal was served via electronic
`
`mail to Patent Owner at the following email addresses of record:
`
`Brausa, Adam R. ABrausa@mofo.com
`Davis, Kira A KiraDavis@mofo.com
`Weires, Rebecca RWeires@mofo.com
`Durie, Daralyn J. DDurie@mofo.com
`Regeneron-MoFo-IPR Regeneron-MoFo-IPR@mofo.com
`
`
`
`
`DATED: September 18, 2023
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`By /Raymond N. Nimrod/
`Raymond N. Nimrod (Reg. No. 31,987)
`raynimrod@quinnemanuel.com
`QUINN EMANUEL URQUHART
` & SULLIVAN, LLP
`51 Madison Ave., 22nd Floor
`New York, NY 10010
`Tel: (212) 849-7000
`Fax: (212) 849-7100
`
`
`5
`
`